Clinical Trial Search

Primary: AUCinf: Area Under Plasma Concentration-time Curve From 0 to Infinity in Fasted Condition — 180.4; 195.2; 4486; 4332 hour*nanogram/millilitre

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 6; 4 Participants

Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants

Primary: Part A: Number of Participants With All Non-serious Adverse Events (AEs) and Serious AEs (SAEs) Following Administration of Oral Dose — 1; 2; 3; 1 Participants

Primary: Number of Participants That Had bRBC Detectable at 70 Days Post-intervention — 5 participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 3; 4; 4 Participants

Primary: Number Of Participants Experiencing Treatment-emergent Adverse Events — 0; 0; 0; 0 participants

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Number of Participants With TEAEs, SAEs, and Severe TEAEs - Part 1: SAD — 1; 1; 2; 2 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 19; 11; 5 Participants

Primary: Dogoxin Plasma Data for Cmax — 1530.188; 2432.908 pg/mL

Primary: Percentage of Subjects With Drug-related Adverse Events — 6.3; 0.0; 16.7; 0.0 Percentage of participants

Primary: Part A: Area Under the Concentration-time Curve of Alteplase in Plasma Over the Time Interval From 0 up to the Last Quantifiable Data Point (AUC0-tz)

Primary: Maximum Tolerated Dose (MTD) of Olaparib Administered in Combination With Onalespib — 300; 200 mg

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CIS43LS Product Administration — 4; 1; 5; 3 Participants